MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Core Insights - MAIA Biotechnology, Inc. has reported promising overall survival results for patients treated with ateganosine in its Phase 2 THIO-101 clinical trial for non-small cell lung cancer (NSCLC) [2][4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine, a first-in-class telomere-targeting agent [8] - The company aims to improve and extend the lives of cancer patients through innovative therapies [8] Clinical Trial Highlights - In the ongoing Phase 2 THIO-101 trial, eight patients have shown overall survival beyond two years without subsequent lines of therapy [2] - The trial has treated a total of 79 patients in Parts A and B, with Part C currently enrolling up to 48 participants in Asia and Europe [2][5] - The treatment regimen of ateganosine followed by cemiplimab has demonstrated an acceptable safety profile in a heavily pre-treated population [2][7] Mechanism of Action - Ateganosine works by targeting telomeres, which are crucial for cancer cell survival and resistance to therapies, leading to selective cancer cell death [4] - The drug induces immune responses that may enhance the effectiveness of subsequent treatments with PD-(L)1 inhibitors [4] Survival Data - One patient in third-line therapy achieved survival of 33 months, while four patients in second-line therapy had survival exceeding 30 months [6] - The expected survival for heavily pre-treated patients is significantly lower, at 5.8 months for standard treatments [6]